Cipher Pharmaceuticals Stock Performance
| CPH Stock | CAD 14.81 -0.35 -2.31% |
Cipher Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The entity retains a Market Volatility (i.e., Beta) of 0.0733, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Cipher Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cipher Pharmaceuticals is expected to be smaller as well. Cipher Pharmaceuticals at this moment retains a risk of 1.8%. Please validate Cipher Pharmaceuticals the relationship between the maximum drawdown and skewness .
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared with the broader market, risk-adjusted returns on Cipher Pharmaceuticals rank lower than 2% of all global equities and portfolios over the last 90 days. This score becomes more useful when investors compare it with downside risk, Sharpe Ratio, and current trend stability. In spite of very healthy technical indicators, Cipher Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
1 | What valuation ratios show for Cipher Pharmaceuticals Inc. stock - Market Performance Report Technical Pattern Based Signals - | 12/18/2025 |
2 | Cipher Pharmaceuticals Adjusts Valuation Amid Positive Market Sentiment and Strong Profit Growth - Markets Mojo | 02/06/2026 |
| Begin Period Cash Flow | 39.8 M | |
| Total Cashflows From Investing Activities | -80 M |
Cipher |
Cipher Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,449 in Cipher Pharmaceuticals on December 10, 2025 and sell it today you would earn a total of 32.00 from holding Cipher Pharmaceuticals or generate 2.21% return on investment over 90 days. Cipher Pharmaceuticals is generating 0.0523% of daily returns assuming 1.8033% volatility of returns over the 90 days investment horizon. Simply put, 16% of all stocks have less volatile historical return distribution than Cipher Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cipher Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Cipher Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.81 | 90 days | 14.81 | about 50.0 |
Based on a normal probability distribution, the odds of Cipher Pharmaceuticals to move above the current price in 90 days from now is about 50.0 (This Cipher Pharmaceuticals probability density function shows the probability of Cipher Stock to fall within a particular range of prices over 90 days) .
Cipher Pharmaceuticals Price Density |
| Price |
Predictive Modules for Cipher Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cipher Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Experienced investors tracking Cipher Pharmaceuticals' watch for mean reversion setups: periods when price has deviated significantly from its long-run average, creating an asymmetric risk-reward profile for patient capital.
Cipher Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cipher Pharmaceuticals is not an exception. The market had few large corrections towards the Cipher Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cipher Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cipher Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 0.41 | |
Ir | Information ratio | 0.02 |
Cipher Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cipher Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cipher Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company has C$40.58 Million in debt which may indicate that it relies heavily on debt financing | |
| About 43.0% of the company shares are held by company insiders |
Cipher Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cipher Stock often depends not only on the future outlook of the current and potential Cipher Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cipher Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.6 M | |
| Cash And Short Term Investments | 17.8 M |
Cipher Pharmaceuticals Fundamentals Growth
Cipher Stock prices reflect investors' perceptions of the future prospects and financial health of Cipher Pharmaceuticals, and Cipher Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cipher Stock performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 391.4 M | |||
| Shares Outstanding | 25.37 M | |||
| Price To Earning | 21.55 X | |||
| Price To Book | 2.40 X | |||
| Price To Sales | 7.69 X | |||
| Revenue | 33.36 M | |||
| Gross Profit | 37.2 M | |||
| EBITDA | 11.87 M | |||
| Net Income | 11.54 M | |||
| Cash And Equivalents | 17.84 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 40.58 M | |||
| Debt To Equity | 62.30 % | |||
| Current Ratio | 1.06 X | |||
| Book Value Per Share | 6.14 X | |||
| Cash Flow From Operations | 19.55 M | |||
| Earnings Per Share | 0.94 X | |||
| Market Capitalization | 384.97 M | |||
| Total Asset | 162.51 M | |||
| Retained Earnings | 77.65 M | |||
| Working Capital | 18.61 M | |||
Is Cipher Pharmaceuticals Outperforming?
Cipher Pharmaceuticals performance is measured on a risk-adjusted basis against benchmarks. Return persistence supports interpretability across rolling windows. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Cipher Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cipher (CA:CPH) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Return metrics, performance scores, and risk-adjusted figures shown here are computed from historical price series.
Assumptions
Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Cipher Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Things to note about Cipher Pharmaceuticals performance evaluation
Automated alerts tied to Cipher Pharmaceuticals help investors surface material conditions that may support or challenge the current thesis before they become expensive mistakes. In practice, the value comes from seeing which signals are new, which are persistent, and which are strong enough to justify action.
| The company has C$40.58 Million in debt which may indicate that it relies heavily on debt financing | |
| About 43.0% of the company shares are held by company insiders |
- Analyzing Cipher Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cipher Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cipher Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cipher Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cipher Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cipher Pharmaceuticals' stock. These opinions can provide insight into Cipher Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
More Resources for Cipher Stock Analysis
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Cipher across valuation measures and peers.